NRD
APLS

Nebula Research & Development’s Apellis Pharmaceuticals APLS Stock Holding History

Nebula Research & Development’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,821
Closed -$318K – 336
2023
Q1 		$318K Buy
+4,821
New +$278K 0.56% 91

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's APLS Position: Q2 2023 in Review

Nebula Research & Development sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 4,821 shares — an estimated $318K sold.

Nebula Research & Development first reported a position in APLS in Q1 2023 and held it in 1 quarter. The position peaked at $318K in Q1 2023. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Nebula Research & Development reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Nebula Research & Development sold 4,821 Apellis Pharmaceuticals shares in Q2 2023, an estimated $318K.
  • Nebula Research & Development first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Nebula Research & Development's Apellis Pharmaceuticals position peaked at $318K in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Nebula Research & Development's 13F filing for Q2 2023, filed 14 Aug 2023.